243
Views
6
CrossRef citations to date
0
Altmetric
Letter to the Editor

Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report

, , , , &
Pages 2990-2993 | Received 29 Dec 2017, Accepted 10 Feb 2018, Published online: 04 Apr 2018

References

  • Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349:1543–1554.
  • Graus F, Arino H, Dalmau J. Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood. 2014;123:3230–3238.
  • Rezania K, Soliven B, Baron J, et al. Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature. Leuk Lymphoma. 2012;53:371–380.
  • Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;376: 2570–2581.
  • Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;3:365–368.
  • Verschuuren JJ, Huijbers MG, Plomp JJ, et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev. 2013;9:918–923.
  • Hughes CL, Yorio JT, Kovitz C, et al. Treatment decisions in a man with Hodgkin lymphoma and Guillian-Barré syndrome: a case report. J Med Case Reports. 2014;8:455.
  • Roche JC, Capablo JL, Ara JR. Myasthenia gravis in association with extrathymic neoplasia. Neurologia. 2014;29:507–509.
  • Berrih-Aknin S, Le Panse R. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun. 2014;52:90–100.
  • Gradolatto A, Nazzal D, Truffault F, et al. Both Treg cells and Tconv cells are defective in the myasthenia gravis thymus: roles of IL-17 and TNF-α. J Autoimm. 2014;52:53–63.
  • Greaves P, Clear A, Owen A, et al. Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood. 2013;122:2856–2863.
  • Steidl C, Connors JM, D, Gascoyne D. Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. JCO. 2011;29:1812–1826.
  • Zinzani PL, Vitolo U, Viviani S, et al. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin's lymphoma: experience with 27 patients. Clin Lymphoma Myeloma Leuk. 2015;15:404–408.
  • Corazzelli G, Angrilli F, D'Arco A, et al. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol. 2013;160:207–215.
  • Oki T, Younes A. Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leuk Lymphoma. 2008;49: 883–889.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.